Industry Insights

1. FDA Product Recalls: A Wake-Up Call For Life Sciences Manufacturers 10/9/2024

   Discover why manufacturers must adopt more consumer-centric recall strategies to maintain trust and safeguard their market position.

2. Alzheimer's Disease Pathway 3/24/2025

   Alzheimer’s disease (AD) affects 50 million people globally, causing cognitive decline. Explore the signaling pathways of amyloid beta and tau proteins, linking them to neuronal death and AD symptoms.

3. Private Equity: A New Pillar For Biosimilar Development? 10/13/2020

   The emergence of the biosimilar market represents an interesting opportunity for private equity firms in the global healthcare landscape. Here are the biggest deals from the last two years that suggest there is growing willingness outside of government funding to invest in biosimilar development — especially in emerging markets. 

4. Expert Voices: Why Aren't QC Labs Fully Automated Yet? 10/4/2024

   Leading automation experts chime in on why QC labs, otherwise ideal for robotics, have been slow to adopt and standardize the technology.

5. Continuous Bioprocessing Overtakes Single-Use On List Of Top Technology Trends 10/10/2016

   The desire for innovation in the biopharmaceutical manufacturing industry continues unabated, as companies ramp up their spending on new technologies to improve efficiencies in both upstream and downstream bioprocessing. And while innovation in this industry can be slow to come, the past decade has seen the emergence of several new innovative trends, ranging from the proliferation of single-use devices to growing demand for continuous bioprocessing and modular facilities, according to BioPlan Associates’ 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.

6. How To Build An Effective Protein Degrader 1/29/2025

   Explore four essential questions to ask yourself when developing a PROTAC molecule to ensure you’re on the right track to protein degradation success.

7. ANDA Or 505(B)(2): Choosing The Right Abbreviated Approval Pathway For Your Drug 7/29/2021

   For developers seeking to obtain approval for previously approved drug products in the United States, the U.S. Food and Drug Administration (FDA) offers two abbreviated approval pathways — an abbreviated new drug application (ANDA) and a 505(b)(2) application. Read about these in the available blog.

8. Three Benefits Of Partnering With A CDMO For CGT Manufacturing 2/29/2024

   By leveraging the capabilities of a CDMO, pharmaceutical companies can focus on their core competencies and accelerate the development and delivery of life-saving therapies to patients.

9. Developing More Clinically Relevant Drug-Induced Thrombosis Models 4/9/2024

   Learn how this Blood Vessel-Chip is capable of replicating drug side effects and mimicking the human circulatory system accurately, enhancing drug safety and efficacy in development.

10. Human Performance In Pharma: Strengthening The Biotech Workforce 11/24/2025

    Transforming the pharma workforce requires strategic partnerships and a shift toward behavioral and operational readiness, moving beyond simple technical training to ensure performance and compliance.